BROWSE

Related Researcher

Author

Cho, Yoon-Kyoung
Integrated Nano-Biotech Lab (INBL)
Research Interests
  • Microfluidics, Lab-on-a-chip, personalized biomedical diagnostics, nanobioengineering

ITEM VIEW & DOWNLOAD

All-in-One Centrifugal Microfluidic Device for Size-Selective Circulating Tumor Cell Isolation with High Purity

Cited 2 times inthomson ciCited 0 times inthomson ci
Title
All-in-One Centrifugal Microfluidic Device for Size-Selective Circulating Tumor Cell Isolation with High Purity
Author
Lee, AdaPark, JuheeLim, MinjiSunkara, VijayaKim, Shine YoungKim, Gwang HaKim, Mi-HyunCho, Yoon-Kyoung
Keywords
A-DISC; ISOLATION PLATFORM; CANCER-PATIENTS; WHOLE-BLOOD; LAB; ENUMERATION; ENRICHMENT; CAPTURE; FILTER; CHIP
Issue Date
201411
Publisher
AMER CHEMICAL SOC
Citation
ANALYTICAL CHEMISTRY, v.86, no.22, pp.11349 - 11356
Abstract
Circulating tumor cells (CTCs) have gained increasing attention owing to their roles in cancer recurrence and progression. Due to the rarity of CTCs in the bloodstream, an enrichment process is essential for effective target cell characterization. However, in a typical pressure-driven micro-fluidic system, the enrichment process generally requires complicated equipment and long processing times. Furthermore, the commonly used immunoaffinity-based positive selection method is limited, as its recovery rate relies on EpCAM expression of target CTCs, which shows heterogeneity among cell types. Here, we propose a centrifugal-force-based size-selective CTC isolation platform that can isolate and enumerate C'TCs from whole blood within 30 s with high purity. The device was validated using the MCF-7 breast cancer cell line spiked in phosphate-buffered saline and whole blood, and an average capture efficiency of 61% was achieved, which is typical for size-based filtration. The capture efficiency for whole blood samples varied from 44% to 84% under various flow conditions and dilution factors. Under the optimized operating conditions, a few hundred white blood cells per 1 mL of whole blood were captured, representing a 20-fold decrease compared to those obtained using a commercialized size-based CTC isolation device. In clinical validation, normalized CTC counts varied from 10 to 60 per 7.5 mL of blood from gastric and lung cancer patients, yielding a detection rate of 50% and 38%, respectively. Overall, our CTC isolation device enables rapid and label-free isolation of CTCs with high purity, which should greatly improve downstream molecular analyses of captured CTCs.
URI
http://scholarworks.unist.ac.kr/handle/201301/9682
DOI
http://dx.doi.org/10.1021/ac5035049
ISSN
0003-2700
Appears in Collections:
SLS_Journal Papers

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show full item record

qr_code

  • mendeley

    citeulike

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

MENU